I mean, I thought it was obvious that I didn't need to respond...

I mean, I thought it was obvious that I didn't need to respond given what I have posted previously.

Allogene have been progressing their allogeneic CD19 CAR T in a phase 2 trial for front-line therapy in LBCL, which includes DLBCL. This is the clear front runner for first-in-class allogeneic CD19 CAR T, and they are being aggressive with market capture - even trying to skip ahead of autologous CAR T. Allogenes drug also hasn't killed 5 people.

Roughly 3k DLBCL patients treated with autologous CAR T in the US each year. Relapse rates are roughly 50% at 2 years follow up. 1500 ish DLBCL patients that have failed autologous CAR T. Huge market.

IMUs current market cap is $300M. The opportunity is small in biotech terms and the risk of azer-cel killing someone or being unable to capture market is too high. $70M will go to Precision before commercialization. As has been said previously, IMU need to get to 1.5c for there to be significant upside.

If people here genuinely think they have something, then give a rational explanation as to why management went with con note funding as opposed to publishing these results then raising capital?